<p>EQL Pharma</p>
<p>EQL Pharma 在第二季度经历了来自多个供应商的交付延迟，导致该季度销售损失。交付将会到来，但失去的销售无法在第三和第四季度弥补。预计 2025/26 财年的全年业绩增长将更接近 15% 而非 30%。</p>
<p>交付延迟还导致原定于第二季度进行的产品发布推迟。这些发布将改为在第三季度末或第四季度初进行。</p>
<p>由于交付延迟，EQL Pharma 宣布第二季度的销售预计将略低于 90（85.2）百万瑞典克朗，即与去年同期相比实现单数字增长。</p>
<p>利润也受到影响，但影响程度不如销售显著。预计 2025/26 财年的 EBITDA 利润率将更接近 20% 而非 25%。</p>
<p>这些问题是暂时性的，不会影响公司最近公布的五年目标的实现前景。</p>
<p>所有数据均为初步数据，未经审计。EQL Pharma 第二季度的完整业绩将于 2025 年 11 月 5 日（星期三）公布。</p>
<p>本披露包含 EQL Pharma 根据欧盟市场滥用法规（EU nr 596/2014）和瑞典证券市场法（2007:528）有义务公开的信息。该信息于 2025 年 9 月 22 日 22:35 CET 通过联系人提交发布。</p>
<p>如需更多信息，请联系：</p>
<p>Axel Schörling，</p>
<p>EQL Pharma AB（公众）首席执行官兼总裁</p>
<p>电话：+46 (0) 76 317 90 60</p>
<p>电子邮件：axel.schorling@eqlpharma.com</p>
<p>网站：www.eqlpharma.com</p>
<p>EQL Pharma AB（公众）简介</p>
<p>EQL Pharma AB 专注于开发和销售仿制药，即在医学上等同于原研药的药物。该公司目前在北欧市场推出了 46 种小众仿制药（即与原研药竞争有限的仿制药）。除了这些产品外，还有大量小众仿制药的管道计划于 2025 年及以后推出。该业务目前完全专注于处方药，包括医院产品，主要在北欧和欧洲市场。EQL Pharma AB 在隆德运营，并在纳斯达克斯德哥尔摩证券市场上市。EQL Pharma AB 与欧盟和亚洲等地的领先合同制造商和大型制药公司开展广泛的开发合作。</p>
<p>https://news.cision.com/eql-pharma/r/delivery-delays-mean-that-the-second-quarter-and-thus-the-full-year-2025-26-will-be-weaker-than-expe%2Cc4238282</p>
<p>新闻稿 2025-09-22 盈利警告</p>

平等行业权重 ETF - ALPS

<p>EQL Pharma 报告称，第二季度供应商交货延迟导致销售损失，并对 2025/26 财年的前景产生了负面影响，预计增长将接近 15%，而非 30%。第二季度的销售预计将略低于 90 百万瑞典克朗，反映出同比的个位数增长。预计 EBITDA 利润率将约为 20%。原定于第二季度的产品发布已推迟至第三季度末或第四季度初。公司保证这些问题是暂时的，不会影响其五年目标。完整的财务结果将于 2025 年 11 月 5 日披露</p>

<p>EQL Pharma</p>
<div class="lb-trans"><p>EQL Pharma</p>
</div><p>EQL Pharma has experienced delays in deliveries from several suppliers during the second quarter, resulting in lost sales during the quarter. Deliveries will come, but the lost sales cannot be made up for in the third and fourth quarters. Full-year results for the 2025/26 financial year are expected to be closer to 15 than 30 percent growth.</p>
<div class="lb-trans"><p>EQL Pharma 在第二季度经历了来自多个供应商的交付延迟，导致该季度销售损失。交付将会到来，但失去的销售无法在第三和第四季度弥补。预计 2025/26 财年的全年业绩增长将更接近 15% 而非 30%。</p>
</div><p>The delivery delays have also led to postponements of launches that were supposed to take place in Q2. These will instead take place towards the end of Q3 or early in Q4.</p>
<div class="lb-trans"><p>交付延迟还导致原定于第二季度进行的产品发布推迟。这些发布将改为在第三季度末或第四季度初进行。</p>
</div><p>As a result of the delivery delays, EQL Pharma announces that sales in the second quarter are expected to land just under 90 (85.2) MSEK, i.e. a single-digit growth compared to the same quarter last year.</p>
<div class="lb-trans"><p>由于交付延迟，EQL Pharma 宣布第二季度的销售预计将略低于 90（85.2）百万瑞典克朗，即与去年同期相比实现单数字增长。</p>
</div><p>Profit is also affected, but not as significantly as sales. Here, an EBITDA margin closer to 20 than 25 percent is expected for the full year 2025/26.</p>
<div class="lb-trans"><p>利润也受到影响，但影响程度不如销售显著。预计 2025/26 财年的 EBITDA 利润率将更接近 20% 而非 25%。</p>
</div><p>The problems are of a temporary nature and do not affect the prospects of delivering on the Company's recently communicated five-year target.</p>
<div class="lb-trans"><p>这些问题是暂时性的，不会影响公司最近公布的五年目标的实现前景。</p>
</div><p>All figures are preliminary and unaudited. EQL Pharma's results for the second quarter will be presented in full on Wednesday, November 5, 2025.</p>
<div class="lb-trans"><p>所有数据均为初步数据，未经审计。EQL Pharma 第二季度的完整业绩将于 2025 年 11 月 5 日（星期三）公布。</p>
</div><p>This disclosure contains information that EQL Pharma is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 22-09-2025 22:35 CET.</p>
<div class="lb-trans"><p>本披露包含 EQL Pharma 根据欧盟市场滥用法规（EU nr 596/2014）和瑞典证券市场法（2007:528）有义务公开的信息。该信息于 2025 年 9 月 22 日 22:35 CET 通过联系人提交发布。</p>
</div><p>For more information contact:</p>
<div class="lb-trans"><p>如需更多信息，请联系：</p>
</div><p>Axel Schörling,</p>
<div class="lb-trans"><p>Axel Schörling，</p>
</div><p>CEO &amp; President EQL Pharma AB (publ)</p>
<div class="lb-trans"><p>EQL Pharma AB（公众）首席执行官兼总裁</p>
</div><p>Phone: +46 (0) 76 317 90 60</p>
<div class="lb-trans"><p>电话：+46 (0) 76 317 90 60</p>
</div><p>E-mail: axel.schorling@eqlpharma.com</p>
<div class="lb-trans"><p>电子邮件：axel.schorling@eqlpharma.com</p>
</div><p>Web: www.eqlpharma.com</p>
<div class="lb-trans"><p>网站：www.eqlpharma.com</p>
</div><p>EQL Pharma AB (publ) in short</p>
<div class="lb-trans"><p>EQL Pharma AB（公众）简介</p>
</div><p>EQL Pharma AB specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has 46 niche generics (i.e., generics with limited competition apart from the original drug) launched in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2025 and beyond. The business is currently focused entirely on prescription drugs, including hospital products, mainly in the Nordics and European markets. EQL Pharma AB has its operations in Lund and is listed on Nasdaq Stockholm stock market. EQL Pharma AB carries out extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU and Asia, among others.</p>
<div class="lb-trans"><p>EQL Pharma AB 专注于开发和销售仿制药，即在医学上等同于原研药的药物。该公司目前在北欧市场推出了 46 种小众仿制药（即与原研药竞争有限的仿制药）。除了这些产品外，还有大量小众仿制药的管道计划于 2025 年及以后推出。该业务目前完全专注于处方药，包括医院产品，主要在北欧和欧洲市场。EQL Pharma AB 在隆德运营，并在纳斯达克斯德哥尔摩证券市场上市。EQL Pharma AB 与欧盟和亚洲等地的领先合同制造商和大型制药公司开展广泛的开发合作。</p>
</div><p>https://news.cision.com/eql-pharma/r/delivery-delays-mean-that-the-second-quarter-and-thus-the-full-year-2025-26-will-be-weaker-than-expe%2Cc4238282</p>
<div class="lb-trans"><p>https://news.cision.com/eql-pharma/r/delivery-delays-mean-that-the-second-quarter-and-thus-the-full-year-2025-26-will-be-weaker-than-expe%2Cc4238282</p>
</div><p>Press Release 2025-09-22 Profit warning</p>
<div class="lb-trans"><p>新闻稿 2025-09-22 盈利警告</p>
</div>

交付延迟意味着 2025/26 财年的第二季度以及全年表现将低于预期